Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 31,636 articles published since 2008
|||| 49 

These are the 31636 published articles about Pancreatic Neoplasms that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
376 Editorial KRAS above and beyond - EGFR in pancreatic cancer. 2012

Siveke, Jens T / Crawford, Howard C. · ·Oncotarget · Pubmed #23174662.

ABSTRACT: -- No abstract --

377 Editorial Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. 2012

Adsay, Volkan. · ·Am J Surg Pathol · Pubmed #23154766.

ABSTRACT: -- No abstract --

378 Editorial Endoscopic ultrasound guided fine needle aspiration: results are reproducible. 2012

Almadi, Majid A / Barkun, Alan N. · ·Saudi J Gastroenterol · Pubmed #23150018.

ABSTRACT: -- No abstract --

379 Editorial Pancreatic ductal adenocarcinoma screening: new perspectives. 2012

Pezzilli, Raffaele / Fabbri, Dario / Imbrogno, Andrea. · ·World J Gastroenterol · Pubmed #23049204.

ABSTRACT: Pancreatic ductal adenocarcinoma accounts for more than 90% of all pancreatic cancers and its incidence has increased significantly worldwide. Patients with pancreatic ductal adenocarcinoma have a poor outcome and more than 95% of the people affected die from the disease within 12 mo after diagnosis. Surgery is the first-line treatment in the case of resectable neoplasm, but only 20% of patients are candidates for this approach. One of the reasons there are few candidates for surgery is that, during the early phases of the disease, the symptoms are poor or non-specific. Early diagnosis is of crucial importance to improve patient outcome; therefore, we are looking for a good screening test. The screening test must identify the disease in an early stage in order to be effective; having said this, a need exists to introduce the concept of "early" ductal adenocarcinoma. It has been reported that at least five additional years after the occurrence of the initiating mutation are required for the acquisition of metastatic ability of pancreatic adenocarcinoma and patients die an average of two years thereafter. We have reviewed the most recent literature in order to evaluate the present and future perspectives of screening programs of this deadly disease.

380 Editorial Keys to personalized care in pancreatic oncology. 2012

Crane, Christopher H / Iacobuzio-Donahue, Christine A. · ·J Clin Oncol · Pubmed #23045599.

ABSTRACT: -- No abstract --

381 Editorial Progress in pancreatic cancer: moving beyond gemcitabine? 2012

Basu, Bristi / Jodrell, Duncan. · ·Expert Rev Anticancer Ther · Pubmed #23030218.

ABSTRACT: -- No abstract --

382 Editorial Role of taxanes in pancreatic cancer. 2012

Belli, Carmen / Cereda, Stefano / Reni, Michele. · ·World J Gastroenterol · Pubmed #22969215.

ABSTRACT: Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.

383 Editorial Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. 2012

Danquah, Michael / Singh, Saurabh / Behrman, Stephen W / Mahato, Ram I. · ·Expert Opin Drug Deliv · Pubmed #22954290.

ABSTRACT: -- No abstract --

384 Editorial Age and pancreaticoduodenctomy: is it really about mortality? 2012

Connor, Saxon / Sakowska, Magdalena. · ·HPB (Oxford) · Pubmed #22953999.

ABSTRACT: -- No abstract --

385 Editorial Targeting neuroendocrine tumor: mixing standard options with novel therapies. 2012

Raymond, Eric / Dreyer, Chantal / Faivre, Sandrine. · ·Target Oncol · Pubmed #22918794.

ABSTRACT: -- No abstract --

386 Editorial Pancreatic cancer: steps in the right direction. 2012

Bates, Susan E. · ·Clin Cancer Res · Pubmed #22896690.

ABSTRACT: -- No abstract --

387 Editorial Proceed with caution: vascular resection at pancreaticoduodenectomy. 2012

Tseng, Jennifer F. · ·Ann Surg Oncol · Pubmed #22868922.

ABSTRACT: -- No abstract --

388 Editorial Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma? 2012

Krell, Jonathan / Frampton, Adam E / Jiao, Long R / Stebbing, Justin. · ·Pharmacogenomics · Pubmed #22838942.

ABSTRACT: -- No abstract --

389 Editorial Cost effectiveness of treatment strategies for primary operable pancreatic head adenocarcinoma: do we have more scientific evidence to call for further centralization of care? 2012

Gajdos, Csaba / Schulick, Richard. · ·Ann Surg Oncol · Pubmed #22829004.

ABSTRACT: -- No abstract --

390 Editorial Prognosis of resected pancreatic cancer: is the refined resection margin status dispensable? 2012

Hartwig, Werner / Werner, Jens / Büchler, Markus W. · ·Langenbecks Arch Surg · Pubmed #22820875.

ABSTRACT: -- No abstract --

391 Editorial Flow, firmness, or FNA? Is enhanced EUS fantastic or just fancy? 2012

Romagnuolo, Joseph. · ·Gastrointest Endosc · Pubmed #22817785.

ABSTRACT: -- No abstract --

392 Editorial Research in pancreatic cancer: an update after ASCO 2012. 2012

Saif, Muhammad Wasif. · ·JOP · Pubmed #22797382.

ABSTRACT: -- No abstract --

393 Editorial Autoimmune pancreatitis (AIP) masquerading as pancreatic cancer: cutting is not a crime … for now. 2012

Zyromski, Nicholas J. · ·Dig Dis Sci · Pubmed #22732835.

ABSTRACT: -- No abstract --

394 Editorial New treatments of pancreatic neuroendocrine tumors: why using them? How to use them? 2012

Raymond, Eric / Ruszniewski, Philippe. · ·Target Oncol · Pubmed #22669625.

ABSTRACT: -- No abstract --

395 Editorial [Gastrin without a gastrinoma-editorial]. 2012

Louthan, O. · ·Vnitr Lek · Pubmed #22606745.

ABSTRACT: -- No abstract --

396 Editorial Survival from pancreatic cancer: it's not just about the surgical mortality. 2012

Padbury, Robert T A. · ·Med J Aust · Pubmed #22571298.

ABSTRACT: -- No abstract --

397 Editorial Pancreatic cancer: translational research aspects and clinical implications. 2012

Ansari, Daniel / Chen, Bi-Cheng / Dong, Lei / Zhou, Meng-Tao / Andersson, Roland. · ·World J Gastroenterol · Pubmed #22509073.

ABSTRACT: Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates in pancreatic cancer have generally remained relatively unchanged and the 5-year survival rate is actually below 2%. This paper will address the importance of achieving an early diagnosis and identifying markers for prognosis and response to therapy such as genes, proteins, microRNAs or epigenetic modifications. However, there are still major hurdles when translating investigational biomarkers into routine clinical practice. Furthermore, novel ways of secondary screening in high-risk individuals, such as artificial neural networks and modern imaging, will be discussed. Drug resistance is ubiquitous in pancreatic cancer. Several mechanisms of drug resistance have already been revealed, including human equilibrative nucleoside transporter-1 status, multidrug resistance proteins, aberrant signaling pathways, microRNAs, stromal influence, epithelial-mesenchymal transition-type cells and recently the presence of cancer stem cells/cancer-initiating cells. These factors must be considered when developing more customized types of intervention ("personalized medicine"). In the future, multifunctional nanoparticles that combine a specific targeting agent, an imaging probe, a cell-penetrating agent, a biocompatible polymer and an anti-cancer drug may become valuable for the management of patients with pancreatic cancer.

398 Editorial The confusion around neuroendocrine tumors. 2012

Hendlisz, Alain / Deleporte, Amélie. · ·Curr Opin Oncol · Pubmed #22476192.

ABSTRACT: -- No abstract --

399 Editorial Pancreatic cancer: between bench and bedside. 2012

Melisi, Davide / Budillon, Alfredo. · ·Curr Drug Targets · Pubmed #22458518.

ABSTRACT: -- No abstract --

400 Editorial Pancreas cancer treatment: a surgeon's perspective today. 2012

Coppola, Roberto. · ·Int J Surg · Pubmed #22430280.

ABSTRACT: -- No abstract --

Back · Next